Macrogen

MacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 3, 2022
Macrogen, Conjugation, Company, ADC, Exercise, Telephone, Teplizumab, Therapy, Food, Cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Microdeletion syndrome, GLOBE, Prescription Drug User Fee Act, Anti-CD3 monoclonal antibody, FDA, B7, MCRPC, D, Webcast, Conference, NSCLC, BLA, Acute myeloid leukemia, Half-life, CD123, Large-cell lung carcinoma, Cytokine release syndrome, Research, CEO, Conference call, Clinical trial, Gilead Sciences, PDUFA, ID, NASDAQ, Investor relations, Mab, Melanoma, Patient, Program, Pharmaceutical industry, Vaccine, T1D, Incyte

ET

Key Points: 
  • ET
    ROCKVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended September30, 2022.
  • Revenue for the quarter ended September30, 2022 included MARGENZA net sales of $4.4 million, compared to $3.6million for the quarter ended September30, 2021.
  • R&D Expenses: Research and development expenses were $48.2 million for the quarter ended September30, 2022, compared to $49.8 million for the quarter ended September30, 2021.
  • SG&A Expenses: Selling, general and administrative expenses were $15.4 million for the quarter ended September30, 2022, compared to $17.2 million for the quarter ended September30, 2021.

MacroGenics to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, November 2, 2022
Virtual, CEO, Conference, Cancer, GLOBE, Webcast, Protein engineering, Company, Investor relations, Macrogen, Therapy, Biotechnology, Fine chemical, MD

MacroGenics President & CEO, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Tuesday, November 15 at 10:55 am ET.

Key Points: 
  • MacroGenics President & CEO, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Tuesday, November 15 at 10:55 am ET.
  • MacroGenics President & CEO, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Wednesday, November 30 at 8:50 am ET.
  • Webcasts of the above may be accessed under Events & Presentations in the Investor Relations section of MacroGenics website at http://ir.macrogenics.com/events.cfm .
  • MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

MacroGenics Announces Date of Third Quarter 2022 Financial Results Conference Call

Retrieved on: 
Wednesday, October 26, 2022
Therapy, Telephone, Company, Biotechnology, Webcast, Investor relations, ID, GLOBE, Macrogen, Cancer, Protein engineering, Pharmaceutical industry, MD

ROCKVILLE, MD, Oct. 26, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2022 after the market closes on Thursday, November 3, 2022.

Key Points: 
  • ROCKVILLE, MD, Oct. 26, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2022 after the market closes on Thursday, November 3, 2022.
  • MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, November 3, 2022, at 4:30 pm ET.
  • MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer.
  • MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies

Retrieved on: 
Monday, October 17, 2022
Oncology, Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, U.S. Securities and Exchange Commission, Protein engineering, Therapy, CRS, SEC, Medicine, Risk, Acute myeloid leukemia, AML, DART, CD3, Cytokine release syndrome, NASDAQ, Microdeletion syndrome, MDS, Biotechnology, Patient, Lymphatic system, Research, Twitter, Security (finance), Program, Bispecific monoclonal antibody, Multimedia, Investment, Partnership, Gilead Sciences, Senior, Cancer, Private Securities Litigation Reform Act, HIV, EPS, CD123, Exercise, MD, Doctor of Philosophy, Industry, Science, Blood, Lists of disasters, Toxicity, CEO, Macrogen, GILD, IPR, COVID-19, Half-life, Pharmaceutical industry

Gilead Sciences, Inc. (NASDAQ: GILD) and MacroGenics (NASDAQ: MGNX) today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics DART platform, and two additional bispecific research programs.

Key Points: 
  • Gilead Sciences, Inc. (NASDAQ: GILD) and MacroGenics (NASDAQ: MGNX) today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics DART platform, and two additional bispecific research programs.
  • View the full release here: https://www.businesswire.com/news/home/20221016005052/en/
    A leader in the bispecific antibody space, MacroGenics has extensive experience applying its proprietary DART platform to develop novel therapeutics.
  • MacroGenics bispecific expertise naturally complements Gileads portfolio strengths in immuno-oncology and our growing hematology franchise, said Bill Grossman, MD, PhD, Senior Vice President, Oncology Clinical Development, Gilead Sciences.
  • Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

Illumina Unveils Revolutionary NovaSeq X Series to Rapidly Accelerate Genomic Discoveries and Improve Human Health

Retrieved on: 
Thursday, September 29, 2022
YouTube, Double-barrelled name, Software, Health, Therapy, Particle-size distribution, Time, Agriculture, Acceleration, Efficiency, Twitter, Illumina, Inc., Disease, ORA, LinkedIn, Population, Lists of diseases, Review, U.S. Securities and Exchange Commission, Patient, Genetics, Cancer, Reproductive health, CEO, Technology, Instagram, WGS, Dry ice, Doctor of Philosophy, Genetic distance, NASDAQ, Genomics, SAN, Heart, Data compression, Research, DNA, Security (finance), SBS, Form 10-K, Broad Institute, Genome, Chemistry, Antibiotics, Recycling, Medical imaging, Computer data storage, Illumina, Facebook, Macrogen

SAN DIEGO, Sept. 29, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of the NovaSeq™ X Series (NovaSeq X and NovaSeq X Plus), new production-scale sequencers that will push the limits of what is possible with genomic medicine, enabling faster, more powerful, and more sustainable sequencing. Using revolutionary new technology, NovaSeq X Plus can generate more than 20,000 whole genomes per year – 2.5 times the throughput of prior sequencers – greatly accelerating genomic discovery and clinical insights, to understand disease and ultimately transform patient lives.

Key Points: 
  • With its NovaSeq X Series, Illumina redesigned every dimension of its world-class sequencers to further increase speed, scale, accuracy, and sustainability.
  • NovaSeq X also significantly reduces waste and environmental impact, reflecting Illumina's commitment to using its technology to support the health of people and the planet.
  • NovaSeq X features a 90% reduction in packaging waste and weight and 50% reduction in plastic usage compared to NovaSeq 6000.
  • "I strongly believe NovaSeq X Series will accelerate our path towards the $100 genome.

Illumina Unveils Revolutionary NovaSeq X Series to Rapidly Accelerate Genomic Discoveries and Improve Human Health

Retrieved on: 
Thursday, September 29, 2022
YouTube, Double-barrelled name, Software, Health, Therapy, Particle-size distribution, Time, Agriculture, Acceleration, Efficiency, Twitter, Illumina, Inc., Disease, ORA, LinkedIn, Population, Lists of diseases, Review, U.S. Securities and Exchange Commission, Patient, Genetics, Cancer, Reproductive health, CEO, Technology, Instagram, WGS, Dry ice, Doctor of Philosophy, Genetic distance, NASDAQ, Genomics, SAN, Heart, Data compression, Research, DNA, Security (finance), SBS, Form 10-K, Broad Institute, Genome, Chemistry, Antibiotics, Recycling, Medical imaging, Computer data storage, Illumina, Facebook, Macrogen

SAN DIEGO, Sept. 29, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of the NovaSeq™ X Series (NovaSeq X and NovaSeq X Plus), new production-scale sequencers that will push the limits of what is possible with genomic medicine, enabling faster, more powerful, and more sustainable sequencing. Using revolutionary new technology, NovaSeq X Plus can generate more than 20,000 whole genomes per year – 2.5 times the throughput of prior sequencers – greatly accelerating genomic discovery and clinical insights, to understand disease and ultimately transform patient lives.

Key Points: 
  • With its NovaSeq X Series, Illumina redesigned every dimension of its world-class sequencers to further increase speed, scale, accuracy, and sustainability.
  • NovaSeq X also significantly reduces waste and environmental impact, reflecting Illumina's commitment to using its technology to support the health of people and the planet.
  • NovaSeq X features a 90% reduction in packaging waste and weight and 50% reduction in plastic usage compared to NovaSeq 6000.
  • "I strongly believe NovaSeq X Series will accelerate our path towards the $100 genome.

Kean Health Launches New STI and Vaginal Microbiome Test Kit

Retrieved on: 
Tuesday, September 13, 2022
Health, Infection, Chlamydia, Woman, Mycoplasma, Risk, STI, Gonorrhea, Data analysis, PH, Patient, Genetics, CEO, Goal, Lactobacillus, Kean v Dunfoy, Diagnosis, HPV, RNA, DNA, Genome, Conditional sentence, Macrogen, Birth control

ROCKVILLE, Md., Sept. 13, 2022 /PRNewswire/ -- Psomagen Incorporated and Kean Health , an at-home health testing provider, announced the launch of Kean V and Kean V+, a vaginal microbiome test.

Key Points: 
  • ROCKVILLE, Md., Sept. 13, 2022 /PRNewswire/ -- Psomagen Incorporated and Kean Health , an at-home health testing provider, announced the launch of Kean V and Kean V+, a vaginal microbiome test.
  • One of the test's key goals is to make it easier for users to get answers about their vaginal health.
  • Kean Health is a provider of at-home health testing services, with a focus on genetics and microbiome profiling.
  • The company offers self-collected test kits for the diagnosis of infections, gut health and vaginal health assessment, and genetic risk of chronic diseases.

GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer

Retrieved on: 
Tuesday, September 6, 2022
Biotechnology, Health, Pharmaceutical, Cardiology, Oncology, Inflammation, University, Astex, Physician, Lymphatic system, Cancer, Research, Form 10-K, Carbohydrate, Food and Drug Administration, Hematology, GSK, AML, Macrogen, Risk, Food, Stanford University School of Medicine, SEC, Chemistry, Acute myeloid leukemia, Cell, U.S. Securities and Exchange Commission, Swarthmore College, Immunology, MD, Economics, Margetuximab, Nasdaq, FDA, Breakthrough therapy, Doctor of Philosophy, Company, Adult, E-selectin, Stanford University, Annual report, Bone marrow, Forward-looking statement, Patient, CMO, Pharmaceutical industry, Glycomimetic, Microbiology, Biology, Brigham

GlycoMimetics, Inc. (Nasdaq: GLYC), a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that Edwin Rock, M.D., Ph.D. has joined the executive leadership team as Chief Medical Officer (CMO).

Key Points: 
  • GlycoMimetics, Inc. (Nasdaq: GLYC), a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that Edwin Rock, M.D., Ph.D. has joined the executive leadership team as Chief Medical Officer (CMO).
  • We are thrilled to have Ed join the GlycoMimetics team.
  • He completed medical residency training at Brigham and Womens Hospital in Boston, MA, a medical oncology fellowship at the University of Pennsylvania, and a postdoctoral fellowship in vaccine engineering at Stanford.
  • Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.

MacroGenics to Participate in Upcoming Investor Conferences

Retrieved on: 
Friday, September 2, 2022
Macrogen, Webcast, Cancer, Investor relations, Protein engineering, Conference, Nasdaq, Biotechnology, Company, Therapy, Doctor of Philosophy, Fine chemical, Management

MacroGenics President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in the Bispecific Panel on Wednesday, September 7, 2022, at 2:40 pm ET.

Key Points: 
  • MacroGenics President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in the Bispecific Panel on Wednesday, September 7, 2022, at 2:40 pm ET.
  • MacroGenics President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on September 28, 2022, at 2:30 pm ET and participate in one-on-one meetings.
  • Webcasts of the abovewill be made available under Events & Presentations in the Investor Relations section of MacroGenics website at http://ir.macrogenics.com/events.cfm .
  • MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

Bright Peak Therapeutics Announces the Appointment of Cancer Immunotherapy Leader Jon Wigginton, M.D., as President of Research and Development

Retrieved on: 
Monday, August 22, 2022
B.S, CA, Patient, Macrogen, University, National Cancer Institute, BMS, Cancer, Immunotherapy, Bristol Myers Squibb, Autoimmune disease, Degenerative disease, IND, Group medical practice in the United States, SAN, Nivolumab, Board, Head, Â, Science, Cytokine, Huangshan, Wigginton, Peak, GLOBE, Coronavirus Scientific Advisory Board (Turkey), Leadership, Biology, Center, Board of directors, Biotechnology, IL-27, NCI, Senior advisor, Director, Society for Immunotherapy of Cancer, National, Drug development, Discovery, Society, Research and development, SITC, Pharmaceutical industry, Vaccine, Research

SAN DIEGO and BASEL, Switzerland, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a biotechnology company developing next-generation precision immunotherapies to treat cancer and autoimmune disease, today announced the appointment of Jon Wigginton, M.D., as its President of Research and Development.

Key Points: 
  • SAN DIEGO and BASEL, Switzerland, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a biotechnology company developing next-generation precision immunotherapies to treat cancer and autoimmune disease, today announced the appointment of Jon Wigginton, M.D., as its President of Research and Development.
  • With a lifelong dedication to improving the lives of patients with cancer, Dr. Wigginton is an internationally recognized expert in immunotherapy drug development.
  • On behalf of the entire company and Board of Directors, I would like to welcome Jon to the team.
  • Prior, he was Chief Medical Officer at MacroGenics, where he led the companys evolution of a fully-integrated clinical-stage cancer immunotherapy organization.